1. Introduction

The Artificial Adaptation Doctrine is a proposed legal and ethical framework for governing the deliberate use of biotechnology, genetic engineering, artificial intelligence, synthetic biology, and related technologies to modify an organism’s ability to adapt to environmental, biological, or social conditions.

It addresses a fundamental question:

When humans artificially alter the capacity of a person, organism, or population to adapt, who has the authority to make that alteration, who bears the risks, and who is legally accountable for its consequences?

The term is not, at present, a universally recognised, standalone doctrine of law. Instead, it can be developed as an interdisciplinary legal concept drawing on established principles of constitutional law, medical consent, environmental protection, genetic privacy, administrative accountability, and biotechnology regulation.

Examples include:

Genetic modification intended to improve resistance to infectious diseases.

Gene therapies intended to correct inherited disorders.

Engineered crops designed to tolerate drought, salinity, or extreme temperatures.

Artificial intelligence systems used to predict or influence biological adaptation.

Proposed genetic modifications intended to help humans tolerate extreme climates.

Heritable genetic changes that could affect future generations.

The doctrine is particularly important when an intervention affects not only the individual receiving it but also future generations, ecosystems, Indigenous communities, or populations that have not consented to the intervention.

2. Meaning and essential elements

The doctrine can be formulated around five principles.

1. Autonomy and informed consent

Biological adaptation technologies must respect bodily integrity, informed consent, and the rights of individuals to make decisions about medical treatment, subject to lawful exceptions.

2. Safety and proportionality

The expected benefits must justify the foreseeable risks. The greater the uncertainty, irreversibility, or potential for intergenerational harm, the stronger the safeguards should be.

3. Equality and non-discrimination

Artificial adaptation must not become a mechanism for genetic discrimination, coercive eugenics, or the exclusion of people who do not possess technologically enhanced traits.

4. Ecological and intergenerational responsibility

The legal assessment must consider effects on biodiversity, ecosystems, future generations, and organisms beyond the intended target.

5. Accountability and public oversight

Developers, researchers, medical practitioners, commercial entities, and regulators must be answerable for unlawful conduct, inadequate safety measures, misleading claims, and failures to monitor foreseeable harm.

These principles provide a framework for legal analysis rather than a claim that every jurisdiction has adopted identical rules.

3. Legal foundations of the doctrine

The Artificial Adaptation Doctrine may be applied through several established areas of law.

A. Constitutional law and human dignity

Artificial adaptation raises constitutional questions when the state or a private institution attempts to determine which biological traits are desirable, who should receive genetic interventions, or whether people may be compelled to undergo them.

The relevant legal principles include:

Human dignity and bodily integrity.

Privacy and personal autonomy.

Equality before the law.

Protection against arbitrary state action.

Freedom from coercive biological experimentation.

In India, these principles may be examined under Articles 14, 19 and 21 of the Constitution, depending on the nature of the interference and the rights involved.

B. Medical law and informed consent

Where artificial adaptation involves gene therapy, experimental medicine, or human genetic modification, valid informed consent is central. Consent should explain the intervention’s purpose, material risks, alternatives, uncertainties, and possible long-term consequences.

Consent alone does not legalise an intervention that is otherwise prohibited, scientifically unjustified, or contrary to applicable regulatory requirements.

C. Environmental and biosafety law

Artificially adapted plants, animals, microorganisms, and gene-drive organisms may escape their intended settings or affect ecosystems. Environmental law therefore provides principles for risk assessment, containment, monitoring, and remediation.

D. Intellectual property and competition law

Patents may encourage research into adaptation technologies, but excessive control over essential technologies can restrict access to treatments and research tools. Patentability, inventorship, licensing, and competition law are consequently relevant to the doctrine.

4. Important case laws

The following cases do not establish a single doctrine called the Artificial Adaptation Doctrine. They provide judicial principles that can be applied to its constituent issues.

Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Facts and legal issue: The Supreme Court considered whether privacy is a fundamental right under the Indian Constitution.

Judgment: The nine-judge Bench unanimously recognised privacy as a fundamental right, grounded in liberty, dignity, and constitutional guarantees.

Relevance to artificial adaptation: Genetic information can reveal inherited disorders, biological relationships, disease susceptibility, and other intimate information. Collecting or using such information for genetic enhancement, screening, or adaptive profiling can therefore raise serious privacy concerns.

The judgment supports constitutional scrutiny of state interference with genetic privacy and bodily autonomy. It does not, however, decide the legality of gene editing or establish an unrestricted right to obtain genetic modification.

Case 2: Suchita Srivastava v. Chandigarh Administration (2009)

Supreme Court of India · (2009) 9 SCC 1

Facts and legal issue: The case concerned reproductive autonomy and the legal authority to make decisions about pregnancy.

Judgment: The Supreme Court recognised reproductive choice as an aspect of personal liberty under Article 21, including the right to make decisions concerning reproduction.

Relevance: Artificial adaptation involving embryos, reproductive genetics, fertility interventions, or heritable modifications may affect fundamental questions of reproductive choice.

The case supports the principle that reproductive decisions require respect for the affected person's autonomy, subject to applicable law. It does not establish that prospective parents have an absolute right to undertake any genetic intervention.

Case 3: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

Facts and legal issue: The dispute concerned medical treatment performed beyond the procedure for which the patient had given consent.

Judgment: The Court explained the requirements of valid medical consent and distinguished consent to one procedure from consent to a materially different procedure. Limited exceptions exist for genuine emergencies.

Relevance: A patient consenting to treatment for a genetic disorder has not necessarily consented to experimental genetic enhancement, reproductive intervention, or the collection and secondary use of genetic data.

Researchers and practitioners should therefore obtain consent that accurately reflects the nature and purpose of the intervention. A general consent form should not be treated as unlimited authorisation for genetic experimentation.

Case 4: Common Cause v. Union of India (2018)

Supreme Court of India · (2018) 5 SCC 1

Facts and legal issue: The case concerned end-of-life autonomy, dignity, and advance medical directives.

Judgment: The Court recognised the legal significance of dignity and patient autonomy in end-of-life decisions and laid down safeguards concerning passive euthanasia and advance directives.

Relevance: Although the case is not about biotechnology, it reinforces the importance of individual dignity and the limits of medical decision-making imposed without proper regard to the person concerned.

In artificial adaptation disputes, the same values may inform questions about invasive procedures, continuing treatment, and respect for the individual's choices.

Case 5: National Legal Services Authority v. Union of India (2014)

Supreme Court of India · (2014) 5 SCC 438

Facts and legal issue: The Court considered the constitutional recognition and rights of transgender persons.

Judgment: The Court affirmed constitutional protections for gender identity, dignity, and equality.

Relevance: Artificial adaptation must not be used to establish a legally enforced hierarchy of supposedly superior and inferior bodies or identities. Genetic screening and biological classification systems may create discriminatory risks if they are used to deny equal treatment or impose stereotyped categories.

The judgment offers an equality-based framework for evaluating such policies, although it does not directly decide genetic discrimination.

Case 6: The Broad Institute, Inc. v. The Regents of the University of California (2025)

U.S. Court of Appeals for the Federal Circuit · May 12, 2025

Facts: The dispute concerned priority of invention for CRISPR-Cas9 technology capable of editing DNA in eukaryotic cells.

Judgment: The Federal Circuit affirmed part of the patent tribunal's decision, vacated its determination concerning conception, and remanded that issue for further proceedings. It held that the tribunal had applied an incorrect legal standard when assessing conception.

FindLaw

+1

Relevance: Artificial adaptation depends partly on the development of technologies that can alter biological characteristics. The case illustrates how courts evaluate inventorship, the technical scope of an invention, written description, and the distinction between conceiving an invention and successfully implementing it.

Legal limitation: Patent ownership does not establish that a genetic intervention is safe, ethically permissible, or legally authorised for clinical use. Patent law and biosafety regulation perform different functions.

Case 7: Evans v. United Kingdom (2007)

European Court of Human Rights, Grand Chamber · Application No. 6339/05

Facts: The case concerned the use of embryos created through IVF after one genetic contributor withdrew consent.

Judgment: The Grand Chamber held that the United Kingdom had not violated Article 8 of the European Convention on Human Rights by applying its statutory consent requirements. The Court emphasised the sensitive ethical questions and the state's discretion in regulating reproductive technology.

HUDOC

+1

Relevance: Artificial adaptation involving embryos raises difficult questions about competing reproductive interests, consent withdrawal, and the legal status of genetic material. The case demonstrates why a clear legal framework is needed before an intervention proceeds.

Case 8: Monsanto Canada Inc. v. Schmeiser (2004)

Supreme Court of Canada · [2004] 1 SCR 902

Facts: The dispute involved genetically modified canola plants found growing on Percy Schmeiser's land and the alleged infringement of Monsanto's patent.

Judgment: The Court found patent infringement based on the use and commercial exploitation of the patented genetic technology. It did not find that the mere presence of patented genes automatically establishes infringement in every circumstance.

Relevance: This case illustrates the tension between proprietary rights over engineered biological technology and the interests of farmers whose land may be affected by the movement of genetically modified organisms.

For artificial adaptation, it highlights the importance of rules governing ownership, accidental spread, liability, and the relationship between patent rights and environmental responsibilities.

5. Indian statutory and regulatory framework

In India, the Artificial Adaptation Doctrine would have to operate through existing legislation and constitutional principles rather than through a standalone statute bearing that name.

India's 1989 biotechnology rules establish a regulatory structure that includes the Review Committee on Genetic Manipulation (RCGM) and the Genetic Engineering Appraisal Committee (GEAC), with responsibilities varying by activity and regulatory stage.

IBKP

+1

The precise approvals required depend on the organism, research method, intended use, and whether the activity involves contained research, clinical treatment, field trials, or environmental release.

Application to human genetic modification

A distinction must be drawn between:

Somatic gene therapy: Genetic changes affecting treated cells, generally not intended to be inherited by descendants.

Germline modification: Changes to reproductive cells or embryos that may be inherited by future generations.

Genetic enhancement: Modification intended to improve a characteristic rather than treat or prevent a disease.

These categories raise different legal and ethical concerns. The legality of a particular intervention must be determined under the applicable Indian regulatory framework; it cannot be inferred from constitutional autonomy alone.

6. Liability under the Artificial Adaptation Doctrine

A workable doctrine would require courts and regulators to identify responsibility at each stage of an intervention.

Researcher or developer liability

Possible liability for negligence, inadequate testing, misrepresentation, breach of research requirements, or failure to follow applicable biosafety safeguards.

Medical practitioner or institution liability

Possible liability for invalid consent, substandard clinical care, unauthorised procedures, or failure to disclose material risks.

Manufacturer or commercial operator liability

Possible product liability, contractual liability, or regulatory sanctions where the relevant legal requirements are satisfied.

Regulatory authority accountability

Judicial review may be available where an authority acts beyond its powers, ignores mandatory procedures, or makes an unlawful decision. The applicable standard depends on the governing statute and facts.

For example, suppose a company develops a genetically modified crop intended to tolerate extreme drought. If the crop spreads beyond authorised trial areas and causes demonstrable environmental damage, the legal inquiry would include the scope of regulatory approval, the foreseeability of spread, compliance with containment measures, causation, and the remedies authorised by law.

The mere occurrence of harm does not automatically establish liability; the relevant statutory provisions and applicable standards of fault or causation must be proved.

7. Major legal challenges

First, uncertainty. Genetic and ecological interventions may produce effects that are difficult to predict. The law must distinguish reasonable scientific uncertainty from avoidable negligence.

Second, intergenerational justice. Heritable modifications affect people who cannot consent at the time of the intervention. This creates questions about reversibility, future autonomy, and the appropriate level of precaution.

Third, discrimination. Artificial adaptation could reinforce social inequalities if access is restricted to wealthy individuals or if employers and insurers misuse genetic information.

Fourth, unequal access. A treatment that improves survival or resilience may create significant social benefits, but exclusive control over essential technologies may impede access.

Fifth, international governance. Genetically modified organisms, biological samples, and research materials may cross borders, while national approval systems differ. International cooperation is therefore important.

8. A proposed legal test for artificial adaptation

As an analytical framework, courts and regulators could assess a disputed intervention through the following questions:

Legality: Is the intervention authorised by the applicable law?

Purpose: Is it intended to treat disease, prevent harm, improve a characteristic, or serve another purpose?

Consent: Have the affected individuals received adequate information and provided valid consent where required?

Scientific evidence: Is the safety and effectiveness evidence appropriate to the intervention's risks?

Proportionality: Are the expected benefits proportionate to the foreseeable harms?

Equality: Does the intervention or policy discriminate unlawfully?

Environmental and intergenerational effects: Could it cause serious or irreversible harm beyond the immediate recipient?

Accountability: Are monitoring, adverse-event reporting, compensation, and corrective measures adequate?

This is a proposed evaluative test, not an existing binding judicial test.

9. Conclusion

The Artificial Adaptation Doctrine offers a useful way to analyse the legal consequences of deliberately changing biological adaptation through genetic engineering, biotechnology, and related technologies. Its strongest legal foundations lie in established principles of autonomy, dignity, equality, informed consent, biosafety, and accountability.

The Indian Supreme Court's decisions in Puttaswamy, Suchita Srivastava, and Samira Kohli provide important foundations for individual autonomy and consent. Evans illustrates the complexity of reproductive decisions, while Monsanto Canada and the CRISPR patent litigation demonstrate the separate but related issues of biological ownership, innovation, and regulatory oversight.

The central proposition is that the power to modify biological adaptation must remain subject to law, scientific scrutiny, human dignity, and responsibility for foreseeable harm. The doctrine is best understood as a proposed synthesis of existing legal principles, not as a formally recognised independent cause of action.